ACRX — AcelRx Pharmaceuticals Share Price
Last Trade - 00:00- $111.29m
- $63.99m
- $5.54m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 17.36 | 8 | 2.15 | 2.29 | 5.42 | 15.77 | 69.09 | -22.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.
Directors
- Adrian Adams (70)
- Vincent Angotti (53)
- Pamela Palmer (58)
- Raffi Asadorian (51)
- Badri Dasu (58)
- Richard Afable (67)
- Marina Bozilenko (55)
- Mark Edwards (63)
- Stephen Hoffman (67)
- Howard Rosen IND (63)
- Mark Wan (55)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- July 13th, 2005
- Public Since
- February 11th, 2011
- No. of Shareholders
- 12
- No. of Employees
- 54
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 119,102,999
- Address
- 25821 INDUSTRIAL BOULEVARD, SUITE 400, HAYWARD, 94545
- Web
- http://www.acelrx.com
- Phone
- +1 6502163500
- Auditors
- OUM & CO. LLP
Latest News for ACRX
Upcoming events for ACRX
Q3 2021 AcelRx Pharmaceuticals Inc Earnings Release
Similar to ACRX
4D PHARMA ADR REP 8 ORD
NASDAQ Global Market
89BIO ORD
NASDAQ Global Market
ACCELERON PHARMA ORD
NASDAQ Global Market
ADAGENE 4 ADR REP 5 ORD
NASDAQ Global Market
ADAGIO THERAPEUTICS ORD
NASDAQ Global Market
FAQ
As of Today at 20:44 UTC, shares in AcelRx Pharmaceuticals are trading at $0.93. This share price information is delayed by 15 minutes.
Shares in AcelRx Pharmaceuticals last closed at $0.93 and the price had moved by -27% over the past 365 days. In terms of relative price strength the AcelRx Pharmaceuticals share price has underperformed the S&P500 Index by -44.62% over the past year.
The overall consensus recommendation for AcelRx Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
AcelRx Pharmaceuticals does not currently pay a dividend.
AcelRx Pharmaceuticals does not currently pay a dividend.
AcelRx Pharmaceuticals does not currently pay a dividend.
To buy shares in AcelRx Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.93, shares in AcelRx Pharmaceuticals had a market capitalisation of $111.29m.
Here are the trading details for AcelRx Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ACRX
Based on an overall assessment of its quality, value and momentum AcelRx Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AcelRx Pharmaceuticals is $6.67. That is 613.83% above the last closing price of $0.93.
Analysts covering AcelRx Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AcelRx Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -62.18%.
As of the last closing price of $0.93, shares in AcelRx Pharmaceuticals were trading -39.4% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for AcelRx Pharmaceuticals.
AcelRx Pharmaceuticals' management team is headed by:
- Adrian Adams -
- Vincent Angotti -
- Pamela Palmer -
- Raffi Asadorian -
- Badri Dasu -
- Richard Afable -
- Marina Bozilenko -
- Mark Edwards -
- Stephen Hoffman -
- Howard Rosen - IND
- Mark Wan -
We do not have data on AcelRx Pharmaceuticals' shareholders